메뉴 건너뛰기




Volumn 26, Issue 1, 2012, Pages

What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CARDIAC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LAPATINIB; METHOTREXATE; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

EID: 84856799855     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (18)

References (30)
  • 1
    • 33646375742 scopus 로고    scopus 로고
    • Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
    • Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-9.
    • (2006) J Clin Oncol , vol.24 , pp. 1940-1949
    • Kaufmann, M.1    Hortobagyi, G.N.2    Goldhirsch, A.3
  • 2
    • 84856796568 scopus 로고    scopus 로고
    • Arbeitgeimeinschaft Gynakologische Onkologie (AGO): Recommendations Gynakologische Onkologie Commission Mamma. [English version 11.1.0; updated August 2011.] Available at, Accessed October 29, 2011
    • Arbeitgeimeinschaft Gynakologische Onkologie (AGO): Recommendations Gynakologische Onkologie Commission Mamma. [English version 11.1.0; updated August 2011.] Available at http://www.ago-online.de/index.php?site=mamma_guide_topical=en. Accessed October 29, 2011.
  • 3
    • 13744257860 scopus 로고    scopus 로고
    • Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
    • Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188-94.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 188-194
    • Mauri, D.1    Pavlidis, N.2    Ioannidis, J.P.A.3
  • 4
    • 84856796566 scopus 로고    scopus 로고
    • NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2011., Available at
    • NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2011. Available at www.NCCN.com.
  • 5
    • 75149145066 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort
    • Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377-84.
    • (2010) Lancet , vol.375 , Issue.9712 , pp. 377-384
    • Gianni, L.1    Eiermann, W.2    Semiglazov, V.3
  • 6
    • 79957601951 scopus 로고    scopus 로고
    • Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial
    • Untch M, Fasching AP, Konecny EG, et al. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial. J Clin Oncol. 2011;29:3351-7.
    • (2011) J Clin Oncol , vol.29 , pp. 3351-3357
    • Untch, M.1    Fasching, A.P.2    Konecny, E.G.3
  • 7
    • 80052877920 scopus 로고    scopus 로고
    • Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis
    • abstract
    • von Minckwitz G, Kaufmann M, Kuemmel S et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol. 2011;29(suppl): abstract 1028.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • von Minckwitz, G.1    Kaufmann, M.2    Kuemmel, S.3
  • 8
    • 79954495078 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44)
    • von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). Cancer Res. 2010;70(suppl 24):86s.
    • (2010) Cancer Res , vol.70 , Issue.SUPPL. 24
    • von Minckwitz, G.1    Eidtmann, H.2    Rezai, M.3
  • 9
    • 79953772036 scopus 로고    scopus 로고
    • Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44)
    • abstract S3-1
    • Untch M, Loibl S, Bischoff J, et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res. 2010;70(suppl 24): abstract S3-1.
    • (2010) Cancer Res , vol.70 , Issue.SUPPL. 24
    • Untch, M.1    Loibl, S.2    Bischoff, J.3
  • 10
    • 0033050164 scopus 로고    scopus 로고
    • Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
    • Kuerer HM, Newman LA, Smith TM, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-9.
    • (1999) J Clin Oncol , vol.17 , pp. 460-469
    • Kuerer, H.M.1    Newman, L.A.2    Smith, T.M.3
  • 11
    • 20544460650 scopus 로고    scopus 로고
    • Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    • Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-85.
    • (2005) J Clin Oncol , vol.23 , pp. 3676-3685
    • Buzdar, A.U.1    Ibrahim, N.K.2    Francis, D.3
  • 12
    • 77951624086 scopus 로고    scopus 로고
    • Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro Study
    • Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study. J Clin Oncol. 2010;2024-31.
    • (2010) J Clin Oncol , pp. 2024-2031
    • Untch, M.1    Rezai, M.2    Loibl, S.3
  • 13
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 14
    • 2942659576 scopus 로고    scopus 로고
    • Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    • Pegram MD, Konecny GE, OCallaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96:739-49.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 739-749
    • Pegram, M.D.1    Konecny, G.E.2    Ocallaghan, C.3
  • 15
    • 70350464164 scopus 로고    scopus 로고
    • Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: A Brown University Oncology Group Study
    • Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 2009;27:4693-700.
    • (2009) J Clin Oncol , vol.27 , pp. 4693-4700
    • Sikov, W.M.1    Dizon, D.S.2    Strenger, R.3
  • 16
    • 77953327187 scopus 로고    scopus 로고
    • Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer
    • Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010;21:961-7.
    • (2010) Ann Oncol , vol.21 , pp. 961-967
    • Chen, X.S.1    Nie, X.Q.2    Chen, C.M.3
  • 17
    • 34447545884 scopus 로고    scopus 로고
    • Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN(A)-1 trial
    • Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol. 2007;25:2678-84.
    • (2007) J Clin Oncol , vol.25 , pp. 2678-2684
    • Coudert, B.P.1    Largillier, R.2    Arnould, L.3
  • 18
    • 79952258750 scopus 로고    scopus 로고
    • First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer
    • abstract S3-3
    • Baselga J, Bradbury I, Eidtmann H, et al. First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res. 2010;70(suppl 24): abstract S3-3.
    • (2010) Cancer Res , vol.70 , Issue.SUPPL. 24
    • Baselga, J.1    Bradbury, I.2    Eidtmann, H.3
  • 19
    • 82355192666 scopus 로고    scopus 로고
    • CHER-LOB: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Preliminary safety report with focus on cardiac tolerability
    • abstract 507
    • Guarneri V, Frassoldati A, Cagossi K, et al. CHER-LOB: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Preliminary safety report with focus on cardiac tolerability. J Clin Oncol. 2011;29(suppl): abstract 507.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Guarneri, V.1    Frassoldati, A.2    Cagossi, K.3
  • 20
    • 80052895926 scopus 로고    scopus 로고
    • Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy
    • abstract 506
    • Holmes FA, Nagarwala YM, Espina VA, et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol. 2011;29(suppl): abstract 506.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Holmes, F.A.1    Nagarwala, Y.M.2    Espina, V.A.3
  • 21
    • 79952274439 scopus 로고    scopus 로고
    • Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (NeoSphere)
    • abstract S3-2
    • Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (NeoSphere). Cancer Res. 2010;70(suppl 24): abstract S3-2.
    • (2010) Cancer Res , vol.70 , Issue.SUPPL. 24
    • Gianni, L.1    Pienkowski, T.2    Im, Y.-H.3
  • 22
    • 78651081149 scopus 로고    scopus 로고
    • Impact of treatment characteristics on response of different breast cancer phenotypes: Pooled analysis of the German neo-adjuvant chemotherapy trials
    • von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145-56.
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 145-156
    • von Minckwitz, G.1    Untch, M.2    Nüesch, E.3
  • 23
    • 44849117186 scopus 로고    scopus 로고
    • Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
    • Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008;19: 1090-6.
    • (2008) Ann Oncol , vol.19 , pp. 1090-1096
    • Untch, M.1    Gelber, R.D.2    Jackisch, C.3
  • 24
    • 79952711587 scopus 로고    scopus 로고
    • Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts
    • Rimawi MF, Wiechmann LS, Wang YC, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011;17:1351-61.
    • (2011) Clin Cancer Res , vol.17 , pp. 1351-1361
    • Rimawi, M.F.1    Wiechmann, L.S.2    Wang, Y.C.3
  • 25
    • 80051508992 scopus 로고    scopus 로고
    • TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer
    • abstract 505
    • Chang JCN, Mayer IA, Forero-Torres A, et al. TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol. 2011;29(suppl): abstract 505.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Chang, J.C.N.1    Mayer, I.A.2    Forero-Torres, A.3
  • 26
    • 34247588567 scopus 로고    scopus 로고
    • Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    • Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99:628-38.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 628-638
    • Scaltriti, M.1    Rojo, F.2    Ocaña, A.3
  • 27
    • 80052905474 scopus 로고    scopus 로고
    • Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study
    • abstract 530
    • Loibl S, Bruey JM, von Minckwitz G, et al. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol. 2011;29(suppl): abstract 530.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Loibl, S.1    Bruey, J.M.2    von Minckwitz, G.3
  • 28
    • 82355179662 scopus 로고    scopus 로고
    • Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis
    • abstract 529
    • Bianchini G, Prat A, Pickl M, et al. Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: gene expression analysis. J Clin Oncol. 2011;29(suppl): abstract 529.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Bianchini, G.1    Prat, A.2    Pickl, M.3
  • 29
    • 82355179663 scopus 로고    scopus 로고
    • New molecular biomarkers for resistance to trastuzumab-based in primary HER2 positive breast cancer a translational investigation from the neoadjuvant GeparQuattro study
    • abstract PD0206
    • Huober J, Loibl S, Untch M, et al. New molecular biomarkers for resistance to trastuzumab-based in primary HER2 positive breast cancer a translational investigation from the neoadjuvant GeparQuattro study. Cancer Res. 2010;70 (suppl 24): abstract PD0206.
    • (2010) Cancer Res , vol.70 , Issue.SUPPL. 24
    • Huober, J.1    Loibl, S.2    Untch, M.3
  • 30
    • 84868200988 scopus 로고    scopus 로고
    • Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
    • Jun 12. [Epub ahead of print]
    • von Minckwitz G, Darb-Esfahani S, Loibl S, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2011 Jun 12. [Epub ahead of print]
    • (2011) Breast Cancer Res Treat
    • von Minckwitz, G.1    Darb-Esfahani, S.2    Loibl, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.